USPTO Patent Application: Compositions Targeting Endothelial Cells

ChangeBridge: Patent Apps - Peptides (C07K)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published a patent application from Harvard College detailing novel compositions for targeting endothelial cells. These compositions, which include binders, linkers, and radioactive isotopes, are intended for selective delivery to cells and treating diseases, including cancer.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083866A1) titled "Compositions Targeting Endothelial Cells and Uses Thereof," filed by the President and Fellows of Harvard College. The application describes compositions comprising a binder, linker, and radioactive isotope, optionally with a masking moiety. These compositions are designed to specifically bind to proteins expressed on endothelial cells, such as PMEPA-1, and are intended for selective delivery to cells, treating diseases and disorders, and imaging. It also covers engineered immune cells with chimeric antigen receptors (CARs) that bind to endothelial cell proteins.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in therapeutic and diagnostic technologies related to endothelial cells. Companies involved in drug development, biotechnology, and medical imaging should monitor the progress of this patent and related research for potential licensing opportunities or competitive insights. The application was filed on November 24, 2025, and published on March 26, 2026.

Source document (simplified)

← USPTO Patent Applications

COMPOSITIONS TARGETING ENDOTHELIAL CELLS AND USES THEREOF

Application US20260083866A1 Kind: A1 Mar 26, 2026

Assignee

President and Fellows of Harvard College

Inventors

Ulrich H. von Andrian, Irina Borisovna Mazo, Harold Roderick Neely, Mark Cerasoli

Abstract

Provided herein are compositions, including pharmaceutical compositions, comprising a binder, linker, and a radioactive isotope, and optionally a masking moiety. The compositions can also comprise a first binder connected to a second binder via a first linker, or a binder connected to a payload via a first linker. In some embodiments, the binder or first binder may specifically bind to a protein (e.g., PMEPA-1) expressed on an endothelial cell. Also provided herein are cells comprising a binder that binds to a protein expressed on an endothelial cell. Also provided herein are engineered immune cells comprising a polynucleotide that encodes a chimeric antigen receptor (CAR) that binds to a protein expressed on an endothelial cell. Also provided herein are methods for using these compositions for selective delivery to cells, treating diseases and disorders, and imaging. In some embodiments, the method comprises administering to the subject an effective amount of the composition disclosed herein.

CPC Classifications

A61K 51/1045 A61K 40/11 A61K 40/31 A61K 40/4202 A61K 47/6803 A61K 47/68031 A61K 47/68037 A61K 47/6813 A61K 47/6851 A61P 35/00 C07K 16/30 C07K 16/3007 A61K 2121/00 A61K 2123/00 C07K 2317/31 C07K 2317/569